• This record comes from PubMed

An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis

. 2020 Dec 01 ; 59 (12) : 3858-3868.

Language English Country England, Great Britain Media print

Document type Equivalence Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/pmid32521015

OBJECTIVE: The objective of this study was to investigate whether diacerein has comparable efficacy with celecoxib in pain reduction for treatment in symptomatic knee OA patients. METHODS: This randomized double-blind multicentre non-inferiority trial evaluated diacerein vs celecoxib treatment in patients with Kellgren-Lawrence grade 2-3 and pain scoring ≥4 (10-cm VAS). Patients were randomized to 6 months of treatment with diacerein 50 mg (n = 187) once daily for 1 month and twice daily thereafter, or celecoxib 200 mg (n = 193) once daily. The primary outcome was the change in WOMAC pain score (0-50 cm) at 6 months, and the secondary outcomes were WOMAC sub-scores, VAS pain score, and the OMERACT-OARSI responder rate. RESULTS: In the per protocol population, the adjusted mean change from baseline in the WOMAC pain score was -11.1 ( 0.9) with diacerein (n = 140) and -11.8 (0.9) with celecoxib (n = 148). The intergroup difference was 0.7 (95% CI: -1.8, 3.2; P = 0.597), meeting the non-inferiority margin. Supportive analysis of the intention-to-treat population gave similar results. Other outcomes showed no significant difference between treatment groups. The incidence of treatment-related adverse events was low and balanced between groups, but a greater incidence of diarrhoea occurred with diacerein (10.2% vs 3.7%). Diarrhoea was considered mild-to-moderate in all but one case with complete resolution. CONCLUSIONS: Diacerein was non-inferior to celecoxib in reducing knee OA pain and improving physical function. Diacerein also demonstrated a good safety profile. TRIAL REGISTRATION: A multicentre study on the effect of DIacerein on Structure and Symptoms vs Celecoxib in Osteoarthritis is a National Institutes of Health (NCT02688400) and European Clinical Trial Database (2015-002933-23) registered phase III (Canada) or IV (Europe) study.

See more in PubMed

Woolf AD, Pfleger B.. Burden of major musculoskeletal conditions. Bull World Health Organ 2003;81:646–56. PubMed PMC

Murray CJ, Vos T, Lozano R. et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197–223. PubMed

Hiligsmann M, Cooper C, Arden N. et al. Health economics in the field of osteoarthritis: an expert’s consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2013;43:303–13. PubMed

Litwic A, Edwards MH, Dennison EM, Cooper C.. Epidemiology and burden of osteoarthritis. Br Med Bull 2013;105:185–99. PubMed PMC

Wang H, Bai J, He B, Hu X, Liu D.. Osteoarthritis and the risk of cardiovascular disease: a meta-analysis of observational studies. Sci Rep 2016;6:39672. PubMed PMC

Hall AJ, Stubbs B, Mamas MA, Myint PK, Smith TO.. Association between osteoarthritis and cardiovascular disease: systematic review and meta-analysis. Eur J Prev Cardiol 2016;23:938–46. PubMed

Jordan KM, Arden NK, Doherty M. et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145–55. PubMed PMC

Zhang W, Nuki G, Moskowitz RW. et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010;18:476–99. PubMed

Hochberg MC, Altman RD, April KT. et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012;64:465–74. PubMed

McAlindon TE, Bannuru RR, Sullivan MC. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014;22:363–88. PubMed

National Institute for Health and Care Excellence (NICE). Osteoarthritis: care and management. In: NICE clinical guideline [CG177] 2014. https://www.nice.org.uk/guidance/cg177 (14 November 2018, date last accessed). PubMed

FDA. Drug Safety Communication 13 January 2011: Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit: Boxed Warning Will Highlight Potential for Severe Liver Failure. 2011. https://wayback.archive-it.org/7993/20170111224110/http://www.fda.gov/Drugs/DrugSafety/ucm239821.htm (21 February 2020, date last accessed).

Bhala N, Emberson J, Merhi A, Abramson S. et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769–79. PubMed PMC

Pelletier JP, Martel-Pelletier J, Rannou F, Cooper C.. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum 2016;45(4 Suppl):S22–7. PubMed

Roberts E, Delgado Nunes V, Buckner S. et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis 2016;75:552–9. PubMed PMC

Bruyere O, Cooper C, Pelletier JP. et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2014;44:253–63. PubMed

Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moca Trevisani V.. Diacerein for osteoarthritis. Cochrane Database Syst Rev 2014;2:CD005117. PubMed PMC

Bruyere O, Cooper C, Pelletier JP. et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis—from evidence-based medicine to the real-life setting. Semin Arthritis Rheum 2016;45(4 Suppl):S3–11. PubMed

Bruyère O, Honvo G, Veronese N. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum 2019;49:337–50. PubMed

Rintelen B, Neumann K, Leeb BF.. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med 2006;166:1899–906. PubMed

Bartels EM, Bliddal H, Schondorff PK. et al. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage 2010;18:289–96. PubMed

Panova E, Jones G.. Benefit–risk assessment of diacerein in the treatment of osteoarthritis. Drug Saf 2015;38:245–52. PubMed

Pavelka K, Bruyere O, Cooper C. et al. Diacerein: benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs Aging 2016;33:75–85. PubMed PMC

Franchi-Micheli S, Lavacchi L, Friedmann CA, Zilletti L.. The influence of rhein on the biosynthesis of prostaglandin-like substances in vitro. J Pharm Pharmacol 1983;35:262–4. PubMed

Martel-Pelletier J, Pelletier JP.. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis 2010;2:95–104. PubMed PMC

Petrillo M, Montrone F, Ardizzone S, Caruso I, Porro GB.. Endoscopic evaluation of diacetylrhein-induced gastric-mucosal lesions. Curr Ther Res Clin Exp 1991;49:10–5.

Mattei E, Marzoli GA, Oberto G, Brunetti MM. Diacerein effects on the cardiovascular function of the conscious dog following repeated oral administration. RTC Study No. 70600. RTC Research Toxicology Centre. 2009.

Bingham CO, Sebba AI, Rubin BR. et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology 2007;46:496–507. PubMed

Rother M, Lavins BJ, Kneer W. et al. Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial. Ann Rheum Dis 2007;66:1178–83. PubMed PMC

Bingham CO III, Bird SR, Smugar SS, Xu X, Tershakovec AM.. Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis. Osteoarthritis Cartilage 2008;16:1289–93. PubMed

Piaggio G, Elbourne DR, Altman DG. et al. Reporting of noninferiority and equivalence randomized trials. JAMA 2006;295:1152–60. PubMed

Altman R, Asch E, Bloch D. et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039–49. PubMed

Kellgren JH, Lawrence JS.. Radiological assessment of osteoarthosis. Ann Rheum Dis 1957;16:494–502. PubMed PMC

Birbara C, Ruoff G, Sheldon E. et al. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. Curr Med Res Opin 2006;22:199–210. PubMed

Bingham CO III, Smugar SS, Wang H, Tershakovec AM.. Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo. Rheumatology 2009;48:1122–7. PubMed

Schnitzer TJ, Kivitz A, Frayssinet H, Duquesroix B.. Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study. Osteoarthritis Cartilage 2010;18:629–39. PubMed

Ehrich EW, Davies GM, Watson DJ. et al. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 2000;27:2635–41. PubMed

International Conference on Harmonization (ICH) E9 Expert Working Group. ICH Harmonised Tripartite Guideline Topic E9: Statistical principles for clinical trials. Stat Med 1999;18:1905–42. PubMed

Committee for Proprietary Medicinal Products (CPMP). CPMP/EWP/482/99 Final. Points to consider on switching between superiority and non-inferiority. London: European Medicines Agency, 2000. https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-switching-between-superiority-non-inferiority_en.pdf (21 February 2020, date last accessed).

Pham T, Van Der Heijde D, Lassere M. et al. Outcome variables for osteoarthritis clinical trials: the OMERACT-OARSI set of responder criteria. J Rheumatol 2003;30:1648–54. PubMed

Nguyen M, Dougados M, Berdah L, Amor B.. Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum 1994;37:529–36. PubMed

Pelletier JP, Yaron M, Haraoui B. et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum 2000;43:2339–48. PubMed

Zheng WJ, Tang FL, Li J. et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a randomized, multicenter, double-dummy, diclofenac-controlled trial in China. APLAR J Rheumatol 2006;9:64–9.

Brahmachari B, Chatterjee S, Ghosh A.. Efficacy and safety of diacerein in early knee osteoarthritis: a randomized placebo-controlled trial. Clin Rheumatol 2009;28:1193–8. PubMed

Singh K, Sharma R, Rai J.. Diacerein as adjuvant to diclofenac sodium in osteoarthritis knee. Int J Rheum Dis 2012;15:69–77. PubMed

Hochberg MC, Martel-Pelletier J, Monfort J. et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2016;75:37–44. PubMed PMC

Reginster JY, Dudler J, Blicharski T, Pavelka K.. Pharmaceutical-grade chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis 2017;76:1537–43. PubMed PMC

Pelletier JP, Martel-Pelletier J.. Diacerein-containing products: same risk of diarrhoea? Aging Clin Exp Res 2018;30:411–2. PubMed

Newman CB, Preiss D, Tobert JA. et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2019;39:e38–e81. PubMed

McAlindon TE, Driban JB, Henrotin Y. et al. OARSI Clinical Trials Recommendations: design, conduct, and reporting of clinical trials for knee osteoarthritis. Osteoarthritis Cartilage 2015;23:747–60. PubMed

See more in PubMed

ClinicalTrials.gov
NCT02688400

Find record

Citation metrics

Archiving options